Archive for the ‘Eliquis – Apixaban’ Category
Stephan Moll, MD writes….
The pharmaceutical company Portola reported today (May 8th, 2013) on the findings of their human volunteer study of their blood thinner antidote PRT4445 (ClinicalTrials.gov Identifier: NCT01758432 – medical details of the study design are here, study NCT01758432. This dug is in early development. In the study, healthy volunteers who had taken the new oral blood thinner Eliquis (Apixaban) received the reversal agent. The study showed a “rapid and sustained and dose-related reversal” of the blood thinning effect of Eliquis” and “no serious adverse events”. Read the rest of this entry »
Stephan Moll, MD writes…
Apixaban (Eliquis) is one of the 3 new oral blood thinners. It is NOT approved at this point to prevent or treat DVT or PE (also referred to as venous thromboembolism or VTE). It is, however, FDA-approved for the use in patients with irregular heart beat (atrial fibrillation) to prevent stroke. As the studies on VTE have not been completed and as the drug is not FDA-approved for VTE, I would NOT use it off label in patients with VTE. However, for the health care professionals who prescribes apixaban for atrial fibrillation, we have made available the apixaban guideline (here) Read the rest of this entry »
Stephan Moll, MD writes… Another new oral blood thinner (Eliquis = apixaban) was approved by the FDA on Dec 28th, 2012 – to be used by patients with irregular heart beat (atrial fibrillation) to prevent stroke. The drug is NOT yet FDA-approved for treatment of patients with DVT or PE. Clinical trials evaluating Eliquis for this indication are still ongoing. Read the rest of this entry »
Eliquis (Apixaban) is one of the 4 promising new oral “blood thinners” that (a) do not require monitoring of its “blood thinning” (anticoagulant) effect, i.e. do not require INR monitoring, and (b) do not interfere with vitamin K in the diet, i.e. patients can eat what they want. Read the rest of this entry »